225 related articles for article (PubMed ID: 30995847)
21. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
22. New approaches to the treatment of older adults with acute lymphoblastic leukemia.
Schwartz M; Wieduwilt MJ
Semin Hematol; 2020 Jul; 57(3):122-129. PubMed ID: 33256901
[TBL] [Abstract][Full Text] [Related]
23. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
[TBL] [Abstract][Full Text] [Related]
24. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
25. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
27. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
28. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C; Sartor C; Dominietto A; Zappone E; Arpinati M; Marconi G; Cristiano G; Nanni J; Parisi S; Barbato F; Paolini S; Soverini S; Terragna C; Robustelli V; Testoni N; Chirumbolo G; Curti A; Cavo M; Bonifazi F
Hematol Oncol; 2021 Oct; 39(4):580-583. PubMed ID: 33963566
[No Abstract] [Full Text] [Related]
29. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
Rafei H; Kantarjian HM; Jabbour EJ
Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
Assi R; Kantarjian H; Short NJ; Daver N; Takahashi K; Garcia-Manero G; DiNardo C; Burger J; Cortes J; Jain N; Wierda W; Chamoun S; Konopleva M; Jabbour E
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):897-901. PubMed ID: 28927784
[TBL] [Abstract][Full Text] [Related]
32. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
Advani A
Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
[TBL] [Abstract][Full Text] [Related]
33. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Pirosa MC; Leotta S; Cupri A; Stella S; Martino EA; Scalise L; Sapienza G; Calafiore V; Mauro E; Spadaro A; Vigneri P; Di Raimondo F; Milone G
Chemotherapy; 2018; 63(4):220-224. PubMed ID: 30372691
[TBL] [Abstract][Full Text] [Related]
35. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
36. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
37. Current and future management of Ph/BCR-ABL positive ALL.
Maino E; Sancetta R; Viero P; Imbergamo S; Scattolin AM; Vespignani M; Bassan R
Expert Rev Anticancer Ther; 2014 Jun; 14(6):723-40. PubMed ID: 24611626
[TBL] [Abstract][Full Text] [Related]
38. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
39. Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy.
Brown PA; Shah B
J Natl Compr Canc Netw; 2018 May; 16(5S):651-655. PubMed ID: 29784748
[TBL] [Abstract][Full Text] [Related]
40. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]